Valuation: GlaxoSmithKline plc

Market Cap 73.86B 96.76B 88.13B 81.2B 139B 8,960B 146B 988B 393B 4,894B 363B 355B 15,358B P/E 2026 *
14.9x
P/E 2027 * 11.9x
Enterprise Value 95.76B 125B 114B 105B 180B 11,615B 189B 1,281B 509B 6,344B 471B 461B 19,910B EV / Sales 2026 *
2.83x
EV / Sales 2027 * 2.64x
Free-Float
94.95%
Yield 2026 *
3.78%
Yield 2027 * 4.06%
Manager TitleAgeSince
Chief Executive Officer 52 31/12/2025
Director of Finance/CFO 64 30/04/2023
Compliance Officer - 31/07/2018
Director TitleAgeSince
Director/Board Member 52 05/05/2026
Director/Board Member 64 31/12/2017
Chairman 67 31/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.33%-4.76%+25.01%+75.64% 452B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales 33.83B 44.32B 40.36B 37.19B 63.47B 4,104B 66.71B 453B 180B 2,241B 166B 163B 7,035B 35.28B 46.21B 42.09B 38.78B 66.18B 4,279B 69.55B 472B 188B 2,337B 173B 170B 7,335B
Net income 4.92B 6.44B 5.87B 5.41B 9.23B 597B 9.7B 65.8B 26.15B 326B 24.17B 23.66B 1,023B 6.11B 8B 7.29B 6.72B 11.46B 741B 12.05B 81.74B 32.49B 405B 30.03B 29.39B 1,270B
Net Debt 21.89B 28.68B 26.12B 24.07B 41.07B 2,655B 43.16B 293B 116B 1,450B 108B 105B 4,552B 19.18B 25.12B 22.88B 21.08B 35.98B 2,326B 37.81B 257B 102B 1,271B 94.25B 92.27B 3,987B
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline plc